GlassScriptPhysician profile
Frederick M Costello
NPI 1285851337
$5,339.27
in general payments reported to CMS, 2019-2025
30 companies · $807 in 2025
The $807 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $194 · 2021: $318 · 2022: $324 · 2023: $2,973 · 2024: $614 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204 · Travel and Lodging: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.88 |
| Travel and Lodging | $1,189.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,256.93 | 2021-2024 | Supera, Jeti, Coroflow |
| Edwards Lifesciences Corporation | $442.53 | 2019-2023 | Edwards Sapien Xt Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $314.04 | 2022-2025 | Pulseselect, Corevalve Evolut R, Symplicity G3 |
| Impulse Dynamics (USA) INC. | $280.19 | 2023-2025 | Optimizer, Optimizer |
| Pfizer INC. | $251.01 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $235.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $139.10 | 2023-2025 | Farxiga |
| Biotronik INC. | $123.52 | 2020-2023 | Biomonitor, Rivacor 7 Dr-T, Acticor 7 Vr-T Dx |
| E.R. Squibb & Sons, L.L.C. | $115.43 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $110.60 | 2023-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $99.56 | 2023-2024 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.53 | 2023-2025 | Jardiance |
| Bridgebio Pharma, INC. | $96.18 | 2025 | Attruby |
| Abiomed | $93.22 | 2025 | |
| Recor Medical INC | $91.71 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $88.90 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Philips North America LLC | $87.53 | 2023 | |
| Irhythm Technologies, INC. | $83.40 | 2019 | |
| Boston Scientific Corporation | $76.80 | 2023-2025 | General - Therapies |
| Novo Nordisk INC | $46.02 | 2023-2024 | Wegovy, Ozempic |
| Cleerly, INC. | $43.06 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Genzyme Corporation | $29.44 | 2025 | |
| Heartflow, INC. | $26.21 | 2023 | Ffrct |
| Baxter Healthcare | $24.67 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cardiva Medical, INC. | $24.29 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals, LTD. | $16.81 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.71 | 2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $15.17 | 2023 | Xarelto |
| Medtronic Vascular, INC. | $13.91 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.